Genmab A GMAB
NASDAQ GMAB
$52.13 -1.74 (-3.22%)
As of: Nov 12, 2026 · 9:49 AM EST

Genmab A (GMAB) Gross Profit (2023 - 2026)

Updated

Genmab A (GMAB) recorded Gross Profit of $1.07 billion in the quarter ended Jun 30, 2026, up 28.9% from the prior quarter.

Analysis

Genmab A (GMAB) Gross Profit (2023 - 2026) Analysis & Trends

On a TTM basis, Genmab A's Gross Profit came in at $3.73 billion as of Jun 30, 2026; for the year ended Dec 31, 2025, it came in at $3.48 billion, up 16.9% from the prior year.

  • Across earlier years, Gross Profit came in at $2.98 billion in the year ended Dec 31, 2024 (+26.3%) and $2.36 billion in the year ended Dec 31, 2023.
  • The figure for the quarter ended Jun 30, 2026 is the highest quarterly Gross Profit since the quarter ended Sep 30, 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Genmab A 3.47 Bn -3.13 Bn 1.10 Bn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 1.10 Bn
Jun 30, 2026 1.07 Bn
Mar 31, 2026 831.00 Mn
Sep 30, 2025 964.00 Mn
Jun 30, 2025 868.00 Mn
Mar 31, 2025 673.00 Mn
Sep 30, 2024 776.00 Mn
Jun 30, 2024 751.00 Mn
Mar 31, 2024 576.00 Mn
Dec 31, 2023 -9.26 Bn
Sep 30, 2023 4.63 Bn
API Access

Genmab A Gross Profit API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gross-profit&ticker=GMAB&period=max&api_key=YOUR_API_KEY